Načítá se...
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to id...
Uloženo v:
| Vydáno v: | J Kidney Cancer VHL |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Codon Publications
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345528/ https://ncbi.nlm.nih.gov/pubmed/28326248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2014.10 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|